Prevalence of antimicrobial resistance in helicobacter pylori isolates from Iran

African Journal of Biotechnology

Volumn 9, Issue 36, 2010, Pages 5962-5965

  Sirous, M ^a   Mehrabadi, Jalil F ^b   Daryani, N E ^c   Eshraghi, S ^a   Hajikhani, S ^a   Shirazi, M H ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MARS Bioinformatics Institute   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antimicrobial resistance; Helicobacter pylori; MIC

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; FURAZOLIDONE; METRONIDAZOLE; TETRACYCLINE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DISK DIFFUSION; DYSPEPSIA; FEMALE; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; IRAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTIC ULCER; PREVALENCE; STOMACH BIOPSY;

HELICOBACTER PYLORI; NEGIBACTERIA;

EID: 77957327445     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Cavallaro LG, Egan B, O'Morain C, Di Mario F (2006). Treatment of Helicobacter pylori infection. Helicobacter, 11: 36-39.
2. Chaves S, Gadanho M, Tenreiro R, Cabrita J (1999). Assessment of Metronidazole Susceptibility in Helicobacter pylori: Statistical validation and error rate analysis of breakpoints determined by the disk diffusion test. J. Clin. Microbiol. 37: 1628-1631.
3. Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, Kuipers EJ, Kusters JG, Vandenbroucke-Grauls CM (1999). Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline and trovafloxacin in The Netherlands. J. Antimicrob. Chemother. 43: 511-515.
4. Edwards DI (1993). Nitroimidazole drugs-action and resistance mechanisms. I. Mechanisms of action. J. Antimicrob. Chemother. 31: 9-20.
5. Fallahi GH, Maleknejad S (2007). Helicobacter pylori culture and antimicrobial resistance in Iran. Indian J. pediatr. 74: 127-130.
6. Hawkey CJ, Atherton JC, Treichel HC, Thjodleifsson B, Ravic M (2003). Safety and efficacy of 7-day rabeprazole and omeprazole based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. Aliment Pharmacol. Ther. 17: 1065-1074.
7. Hu CT, Wu CC, Lin CY, Cheng CC, Su SC, Tseng YH and Lin NT (2007). Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan. J. Gastroenterol. Hepatol. 22: 720-3.
8. IARC (International Agency for Research on Cancer) (1994). IARC Monograph on the Evaluation of Carcinogenic Risks to Humans: Schitosomes, Liver Flukes and Helicobacter Pylori. Lyon: IARC; Vol. 61.
9. Kuipers EJ (1997). Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer. Aliment Pharmacol. Ther. 11: 71-88.
10. Lamouliatte H, Mégraud F, Delchier JC, Bretagne JF, Courillon-Mallet A, De Korwin JD, Fauchère JL, Labigne A, Fléjou JF, Barthelemy P, Multicentre Study Group (2003). Second-line treatment for failure to eradicate Helicobacter pylori. a randomized trial comparing four treatment strategies. Aliment. Pharmacol. Ther. 18: 791-797.
11. Lui SY, Yeoh KG, Ho B. (2003). Metronidazole-resistant Helicobacter pylori is more prevalent in patients with nonulcer dyspepsia than in peptic ulcer patients in a multiethnic Asian population. J. Clin. Microbiol. 41: 5011-5014.
12. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G (2002). European Helicobacter pylori study group. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 16: 167-180.
13. McNulty C, the PHLS Helicobacter working group: Owen R, Tompkins D, Howtin P, McColl K, Price A, Smith G, Teare L (2001). Helicobacter pylori susceptibility testing by disk siffusion. J. Antimicrob. Chemother. 49: 601-609.
14. Megraud F (2004). Helicobacter pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 53: 1374-84.
15. Nahar S, Mukhopadhyay AK, Khan R, Ahmad MM, Datta S, Chattopadhyay S et al. (2004). Antimicrobial susceptibility of Helicobacter pylori strains isolated in Bangladesh. J. Clin. Microbiol. 42: 4856-4858.
16. NCCLS (2004). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard, 6th edition. NCCLS document M7-A6. Wayne, PA: National Committee for Clinical Laboratory Standards 2004.
17. Nervi G, Liatopoulou S, Cavallaro LG, Gnocchi A, Dal-Bo N, Rugge M, Iori V, Cavestro GM, Maino M, Colla G, Franze A, Di Mario F (2006). Does Helicobacter pylori infection eradication modify peptic ulcer prevalence? A 10 years endoscopical survey. World J. Gastroenterol. 12: 2398-2401.
18. Siavoshi F, Safari F, Doratotaj D, Khatami GR, Fallahi GH, Mirnaseri MM (2006). Antimicrobial resistance of Helicobacter pylori isolates from Iranian adults and children. Arch. Iranian Med. 9: 308-314.
19. Toracchio S, Cellini L, Di Campli E, Cappello G, Malatesta MG, Ferri A, Ciccaglione AF, Grossi L, Marzio L (2000). Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol. Ther. 14: 1639-1643.
20. Toracchio S, Marzio L (2003). Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Dig. Liver Dis. 35: 541-545.
21. Wolle K, Malfertheiner P (2007). Treatment of Helicobacter pylori. Best Pract. Res. Clin. Gastroenterol. 21: 315-324.